Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer.
Heidi Chwan KoRobert J SeagerSarabjot PablaMaria-Fernanda SenosainErik Van RoeyShuang GaoKyle C StricklandRebecca Ann PrevisMichelle F GreenMaureen CooperMary K NeslineStephanie B HastingsKobina Agyaful AmoahShengle ZhangJeffrey M ConroyTaylor J JensenMarcia EisenbergBrian CaveneyEric A SeversonShakti RamkissoonShipra GandhiPublished in: Breast cancer (Dove Medical Press) (2024)
Patients with HER2-low breast cancer have longer survivals yet display no differences in immune-related gene expression when compared to those with HER2-zero cancers. The differences in survival can be attributed to the higher rate of ER-positivity seen in HER2-low breast cancers, compared to HER2-zero tumors.